The 150,000 square feet centre is the first-ever, state-of-the-art biologics development and manufacturing facility in the UK.

The centre serves as the national response capability for the UK government producing vaccines against future pandemics/ emerging infectious diseases, and deliberate/accidental release of biological agents.

Catalent acquired the site at Harwell Campus, Oxfordshire, and will equip it with state-of-the-art drug substance capabilities for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins and other advanced modalities.

Services provided include Daikin Heat Recovery VRV refrigeration system, Altherma heating interface system for LPHW heating services, centralised and localised heat recovery ventilation system, full integration with offsite BMS system, testing, commissioning, and witnessing triggering the manufacturers extended warranty clause